Kratom

Kratom in market and legislative limbo

23-Apr-2024 By Claudia Adrien

“From both a consumer standpoint and from an industry standpoint, it's very hard to know what you can and can't do [with kratom],” industry lawyer Rick Collins told attendees at SupplySide East 2024.

FDA launches directory of ingredients used in products marketed as supplements

07-Mar-2023 By Stephen Daniells

The US Food and Drug Administration (FDA) has unveiled a new Dietary Supplement Ingredient Directory, providing detailed information on 27 ingredients that the Agency states are used in products marketed as dietary supplements.

FDA, FTC combine to tackle opiod claims in kratom warning letters

08-Jul-2022 By Hank Schultz

FDA and FTC have issued four joint warning letters to kratom companies centered on opioid claims. It’s a move that comes on the heels of FDA rejecting an NDI filing on the ingredient for the sixth time.

Part 2

FDA’s Welch on enforcement: ‘Sometimes you need a hammer but, at times, the hammer is not the best option’

28-Jun-2022 By Stephen Daniells

Ingredient-specific actions, as evidenced recently by warning letters to 10 firms in the sports nutrition space, are important to FDA’s regulation of dietary supplements but additional actions are hampered by having to deal with problematic ingredients...

Sixth time still not a charm: FDA again rejects NDIN for kratom

02-Feb-2022 By Stephen Daniells

The FDA has again rejected a new dietary ingredient (NDI) notification for kratom, with one industry lawyer telling us he is not optimistic that anyone will achieve a successful NDI notification for the botanical.

NutraIngredients-USA’s Top 10 most read articles of 2021

23-Dec-2021 By Stephen Daniells

As the year draws to a close, we thought it would be worthwhile to review the most read articles, with NAC, FDA kratom seizures, vitamin D benefits, and Elysium Health making the top 10.

Kratom comment deadline approaches as labs continue to service thriving trade

23-Aug-2021 By Hank Schultz

Today (Aug 24) marks a deadline for public comment on a FDA request for input on the abuse potential of a number of drug substances, including kratom. Even as the regulatory winds shift around the ingredient, analytical labs are lining up to service...

FDA seizes ‘adulterated dietary supplements’ containing kratom worth $1.3 million

24-May-2021 By Stephen Daniells

US Marshals, at the request of the U.S. Food and Drug Administration, seized over 207,000 units of dietary supplements and bulk dietary ingredients containing kratom worth approximately $1.3 million.

Kratom group says CBD regulatory experience offers some lessons

19-Apr-2021 By Hank Schultz

The history of the CBD trade in the US provides a peek into the strategy that kratom proponents may pursue with the goal of a legal trade in the botanical without regulatory impediments, an executive in an advocacy group says.

Study using DILIN data reveals kratom’s liver injury potential

14-Nov-2019 By Hank Schultz

Kratom can cause liver injury in some cases, according to evidence presented recently at a meeting of liver specialists.

AKA says it can see signs that government position on kratom is evolving

03-Aug-2018 By Hank Schultz

Kratom advocates say they can see cracks developing in the wall the federal government has tried to build around access to this botanical.